OMEROS CORP Stock Issued During Period, Value, Conversion of Convertible Securities
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- OMEROS CORP stock issued during period, value, conversion of convertible securities for the quarter ending 2025-09-30 was $7.63M.
- OMEROS CORP stock issued during period, value, conversion of convertible securities for the quarter ending 2025-06-30 was $1.92M.
- OMEROS CORP stock issued during period, value, conversion of convertible securities for fiscal 2025 was $9.54M.
- OMEROS CORP stock issued during period, value, conversion of convertible securities for fiscal 2009 was $91.02M.
| Period end | Stock Issued During Period, Value, Conversion of Convertible Securities 3 month | Stock Issued During Period, Value, Conversion of Convertible Securities 12 month |
|---|---|---|
| 2025-12-31 | $9.54M 10-K · filed 2026-03-31 | |
| 2025-09-30 | $7.63M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $1.92M 10-Q · filed 2026-08-12 | |
| 2009-12-31 | $91.02M 10-K · filed 2012-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |